Christopher Cannon, MD, of Harvard Medical School, talks with DocWire News about the American Diabetes Association (ADA) and the European Association of the Study of Diabetes (EASD) new patient-centered hyperglycemia guidelines in patients who have type 2 diabetes.
Previous guidelines have listed medications and let prescribing caregivers choose from the list without much guidance. The new guidelines are patient-centered and guide the provider step by step to alter therapy based on A1C response, specific medications the patient is already taking, and their concurrent disease states. Dr. Cannon also talks about how this relates to different patient populations, including with patients with atherosclerotic cardiovascular disease (ASCVD), who have recently seen benefit from SGLT2 inhibitors and GLP-I receptor agonists. Research presented at AHA 2018 further supported benefit for the SGLT2 inhibitor dapaglaflozin, as well as research showing benefit from GLP-1 receptor agonists plus standard care. Dr. Cannon noted in the interview that practitioners are now trying to re-orient care around therapies with demonstrated benefit.
This interview was conducted at the American Heart Association 2018 Scientific Sessions in Chicago. To read more DocWire News coverage of AHA 2018, click here.
To see more video interviews with cardiologists, click here.